Drugs / IBI133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06170190 | Jan 2024 → Feb 2025 | cancer of unknown primary site | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06170190 ↗ |